(Date:12/16/2009)... cell culture supplement? InVitria has what scientists have been asking ... that improves the growth and productivity of CHO cells. Developed ... an animal free, well defined and consistent recombinant CHO supplement. ... ... December 16, 2009 -- Scientists working with CHO cells can ...
(Date:12/15/2009)... one of three Department of Energy (DOE) bio-energy research ... protect its valuable intellectual property. , ... ... 2009 -- Surety, LLC , the leading provider ... that the Joint BioEnergy Institute (JBEI), one of three ...
(Date:12/15/2009)... WILMINGTON, Del. and CHARLOTTESVILLE, Va., Dec. 15 ... ) and the University of Virginia (UVa) ... entered into a strategic research collaboration to ... coronary artery disease (CAD) with a secondary ... (Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) ,, The ...
(Date:12/15/2009)... MANOR, N.Y., Dec. 15 On January ... International Society for Medical Publication Professionals (ISMPP) will ... in London, UK. More than 100 attendees are ... forum for publication professionals, editors, publishers, medical writers ... of medical publications and the impact of guidelines ...
Breaking Biology Technology:Online Video of InVitria's Zap-CHO Helps Scientists Maximize CHO Cell Culture Performance 2Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 2Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 3Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 4Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 5AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3Announcing ISMPP EU 2010 - the First European Meeting of the International Society for Medical Publication Professionals, Royal College of Physicians, London, UK, January 20, 2010 2... LAKES, N.J., Nov. 15 Medco Health,Solutions, Inc. (NYSE: ... B.,Snow Jr., and other members of his senior management ... and financial results to,analysts and institutional investors during its ... event, titled "Advancing the,Practice of Pharmacy," is scheduled to ...
... Hoffmann-La Roche Inc. CEO George Abercrombie, Pfizer R&D Head ... & FDA,Commissioner Mark McClellan Headline Agenda at FDA/CMS Summit ... to be a,record year for drug approvals. Unfortunately for ... Food and Drug Administration is on track,to grant marketing ...
... Dr. Brad Thompson, President,and CEO of Oncolytics Biotech ... overview of the company at Toronto CFA Society ... held at the National Club, 303 Bay,Street, Toronto ... Oncolytics is a Calgary-based biotechnology company focused ...
Other Biology Technology:Medco to Webcast Annual Analyst Day Conference 2So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market 2So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market 3Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society 2Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
Human Legumain Affinity Purified Polyclonal Ab...
Human Cystatin F MAb (Clone 292103)...
... Ac-DEVD-CHO is an inhibitor ... The concentration of inhibitor ... activity must be determined ... Ten micromolar inhibitor is ...
Biology Products:Biology NavigationMedical Navigation